http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 14 Oct 2026 14:45:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++DELCATH+SYSTEMS%2C+INC.+++++For%3A+Oct+13++Filed+by%3A+Aharon+Gil/27186707.html si-local-file:///var/storage/secattach/20261014/27186707.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++DELCATH+SYSTEMS%2C+INC.+++++For%3A+Oct+13++Filed+by%3A+Aharon+Gil/27186707.html Wed, 14 Oct 2026 14:45:00 -0400 DCTH http://www.streetinsider.com/Press+Releases/Delcath+Systems%2C+Inc.+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/27052786.html <p> QUEENSBURY, N.Y.--(BUSINESS WIRE)-- Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company’s Compensation Committee, as material inducements to four individuals whose employment commenced in either July 2026 or August 2026. </p><p> The grants, in the form of Restricted Stock Units (RSUs), totaled 34,000 shares of the Company’s common stock and are subject to the terms and conditions of the Company’s 2023 Inducement Plan (“Plan”). The RSUs were granted on September 1, http://www.streetinsider.com/Press+Releases/Delcath+Systems%2C+Inc.+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/27052786.html Fri, 11 Sep 2026 16:01:00 -0400 DCTH http://www.streetinsider.com/Business+Wire/Delcath+Systems%2C+Inc.+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/27052786.html <p> QUEENSBURY, N.Y.--(BUSINESS WIRE)-- Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company’s Compensation Committee, as material inducements to four individuals whose employment commenced in either July 2026 or August 2026. </p><p> The grants, in the form of Restricted Stock Units (RSUs), totaled 34,000 shares of the Company’s common stock and are subject to the terms and conditions of the Company’s 2023 Inducement Plan (“Plan”). The RSUs were granted on September 1, http://www.streetinsider.com/Business+Wire/Delcath+Systems%2C+Inc.+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/27052786.html Fri, 11 Sep 2026 16:01:00 -0400 DCTH http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++DELCATH+SYSTEMS%2C+INC.++++++++++++++++/26925385.html si-local-file:///var/storage/secattach/20260814/26925385.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++DELCATH+SYSTEMS%2C+INC.++++++++++++++++/26925385.html Fri, 14 Aug 2026 08:52:00 -0400 DCTH O.02931219 http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++DELCATH+SYSTEMS%2C+INC.++++++++++++++++/26925385.html si-local-file:///var/storage/secattach/20260814/26925385.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++DELCATH+SYSTEMS%2C+INC.++++++++++++++++/26925385.html Fri, 14 Aug 2026 08:52:00 -0400 DCTH O.02931219 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++DELCATH+SYSTEMS%2C+INC.+++++For%3A+Aug+12/26924963.html si-local-file:///var/storage/secattach/20260814/26924963.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++DELCATH+SYSTEMS%2C+INC.+++++For%3A+Aug+12/26924963.html Fri, 14 Aug 2026 08:10:00 -0400 DCTH O.02931219 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++DELCATH+SYSTEMS%2C+INC.+++++For%3A+Aug+12/26924963.html si-local-file:///var/storage/secattach/20260814/26924963.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++DELCATH+SYSTEMS%2C+INC.+++++For%3A+Aug+12/26924963.html Fri, 14 Aug 2026 08:10:00 -0400 DCTH O.02931219 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++DELCATH+SYSTEMS%2C+INC.+++++For%3A+Jun+30/26880519.html si-local-file:///var/storage/secattach/20260806/26880519.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++DELCATH+SYSTEMS%2C+INC.+++++For%3A+Jun+30/26880519.html Thu, 06 Aug 2026 09:10:00 -0400 DCTH O.02931219 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++DELCATH+SYSTEMS%2C+INC.+++++For%3A+Jun+30/26880519.html si-local-file:///var/storage/secattach/20260806/26880519.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++DELCATH+SYSTEMS%2C+INC.+++++For%3A+Jun+30/26880519.html Thu, 06 Aug 2026 09:10:00 -0400 DCTH O.02931219 http://www.streetinsider.com/Earnings/Delcath+Systems+%28DCTH%29+Tops+Q2+EPS+by+17c/26879533.html <p>Delcath Systems (NASDAQ: DCTH) reported Q2 EPS of $0.07, $0.17 better than the analyst estimate of ($0.10). Revenue for the quarter came in at $29.1 million versus the consensus estimate of $26.6 million.</p><p>For earnings history and earnings-related data on Delcath Systems (DCTH) <a href="http://www.streetinsider.com/ec_earnings.php?q=DCTH">click here</a>.</p> http://www.streetinsider.com/Earnings/Delcath+Systems+%28DCTH%29+Tops+Q2+EPS+by+17c/26879533.html Thu, 06 Aug 2026 08:16:21 -0400 DCTH http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++DELCATH+SYSTEMS%2C+INC.+++++For%3A+Aug+06/26879456.html si-local-file:///var/storage/secattach/20260806/26879456.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++DELCATH+SYSTEMS%2C+INC.+++++For%3A+Aug+06/26879456.html Thu, 06 Aug 2026 08:10:00 -0400 DCTH O.02931219 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++DELCATH+SYSTEMS%2C+INC.+++++For%3A+Aug+06/26879456.html si-local-file:///var/storage/secattach/20260806/26879456.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++DELCATH+SYSTEMS%2C+INC.+++++For%3A+Aug+06/26879456.html Thu, 06 Aug 2026 08:10:00 -0400 DCTH O.02931219 http://www.streetinsider.com/Press+Releases/Delcath+Systems+Reports+Second+Quarter+2026+Results+and+Business+Highlights/26879259.html <p class="bwalignc"> <i>Increases 2026 Revenue Guidance to a Range of $104M to $108M <br></br></i><i>Conference Call Today at 8:30 a.m. Eastern Time</i> </p> <p> QUEENSBURY, N.Y.--(BUSINESS WIRE)-- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial results and business highlights for the second quarter ended June 30, 2026. </p><p> <b>Second Quarter 2026 Financial Results</b> </p><ul class="bwlistdisc"> <li> Total revenue of $29.1 million, compared with $24.2 million in the second quarter of 2025 <ul class="bwlistcircle"> <li> HEPZATO KIT™ revenue of $27.1 million, compared to $22.5 million in the second quarter of 2025 </li> <li> CHEMOSAT® revenue of $2.0 million, compared to $1.7 http://www.streetinsider.com/Press+Releases/Delcath+Systems+Reports+Second+Quarter+2026+Results+and+Business+Highlights/26879259.html Thu, 06 Aug 2026 08:01:00 -0400 A.09642568 DCTH O.02931219 O.20371933 http://www.streetinsider.com/Business+Wire/Delcath+Systems+Reports+Second+Quarter+2026+Results+and+Business+Highlights/26879259.html <p class="bwalignc"> <i>Increases 2026 Revenue Guidance to a Range of $104M to $108M <br></br></i><i>Conference Call Today at 8:30 a.m. Eastern Time</i> </p> <p> QUEENSBURY, N.Y.--(BUSINESS WIRE)-- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial results and business highlights for the second quarter ended June 30, 2026. </p><p> <b>Second Quarter 2026 Financial Results</b> </p><ul class="bwlistdisc"> <li> Total revenue of $29.1 million, compared with $24.2 million in the second quarter of 2025 <ul class="bwlistcircle"> <li> HEPZATO KIT™ revenue of $27.1 million, compared to $22.5 million in the second quarter of 2025 </li> <li> CHEMOSAT® revenue of $2.0 million, compared to $1.7 http://www.streetinsider.com/Business+Wire/Delcath+Systems+Reports+Second+Quarter+2026+Results+and+Business+Highlights/26879259.html Thu, 06 Aug 2026 08:01:00 -0400 A.09642568 DCTH O.02931219 O.20371933 http://www.streetinsider.com/Press+Releases/Delcath+Systems+Reports+Second+Quarter+2026+Results+and+Business+Highlights/26879259.html <p class="bwalignc"> <i>Increases 2026 Revenue Guidance to a Range of $104M to $108M <br></br></i><i>Conference Call Today at 8:30 a.m. Eastern Time</i> </p> <p> QUEENSBURY, N.Y.--(BUSINESS WIRE)-- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial results and business highlights for the second quarter ended June 30, 2026. </p><p> <b>Second Quarter 2026 Financial Results</b> </p><ul class="bwlistdisc"> <li> Total revenue of $29.1 million, compared with $24.2 million in the second quarter of 2025 <ul class="bwlistcircle"> <li> HEPZATO KIT™ revenue of $27.1 million, compared to $22.5 million in the second quarter of 2025 </li> <li> CHEMOSAT® revenue of $2.0 million, compared to $1.7 http://www.streetinsider.com/Press+Releases/Delcath+Systems+Reports+Second+Quarter+2026+Results+and+Business+Highlights/26879259.html Thu, 06 Aug 2026 08:01:00 -0400 A.09642568 DCTH O.02931219 O.20371933 http://www.streetinsider.com/Business+Wire/Delcath+Systems+Reports+Second+Quarter+2026+Results+and+Business+Highlights/26879259.html <p class="bwalignc"> <i>Increases 2026 Revenue Guidance to a Range of $104M to $108M <br></br></i><i>Conference Call Today at 8:30 a.m. Eastern Time</i> </p> <p> QUEENSBURY, N.Y.--(BUSINESS WIRE)-- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial results and business highlights for the second quarter ended June 30, 2026. </p><p> <b>Second Quarter 2026 Financial Results</b> </p><ul class="bwlistdisc"> <li> Total revenue of $29.1 million, compared with $24.2 million in the second quarter of 2025 <ul class="bwlistcircle"> <li> HEPZATO KIT™ revenue of $27.1 million, compared to $22.5 million in the second quarter of 2025 </li> <li> CHEMOSAT® revenue of $2.0 million, compared to $1.7 http://www.streetinsider.com/Business+Wire/Delcath+Systems+Reports+Second+Quarter+2026+Results+and+Business+Highlights/26879259.html Thu, 06 Aug 2026 08:01:00 -0400 A.09642568 DCTH O.02931219 O.20371933 http://www.streetinsider.com/Press+Releases/Delcath+Systems+Reports+Second+Quarter+2026+Results+and+Business+Highlights/26879259.html <p class="bwalignc"> <i>Increases 2026 Revenue Guidance to a Range of $104M to $108M <br></br></i><i>Conference Call Today at 8:30 a.m. Eastern Time</i> </p> <p> QUEENSBURY, N.Y.--(BUSINESS WIRE)-- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial results and business highlights for the second quarter ended June 30, 2026. </p><p> <b>Second Quarter 2026 Financial Results</b> </p><ul class="bwlistdisc"> <li> Total revenue of $29.1 million, compared with $24.2 million in the second quarter of 2025 <ul class="bwlistcircle"> <li> HEPZATO KIT™ revenue of $27.1 million, compared to $22.5 million in the second quarter of 2025 </li> <li> CHEMOSAT® revenue of $2.0 million, compared to $1.7 http://www.streetinsider.com/Press+Releases/Delcath+Systems+Reports+Second+Quarter+2026+Results+and+Business+Highlights/26879259.html Thu, 06 Aug 2026 08:01:00 -0400 A.09642568 DCTH O.02931219 O.20371933 http://www.streetinsider.com/Business+Wire/Delcath+Systems+Reports+Second+Quarter+2026+Results+and+Business+Highlights/26879259.html <p class="bwalignc"> <i>Increases 2026 Revenue Guidance to a Range of $104M to $108M <br></br></i><i>Conference Call Today at 8:30 a.m. Eastern Time</i> </p> <p> QUEENSBURY, N.Y.--(BUSINESS WIRE)-- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial results and business highlights for the second quarter ended June 30, 2026. </p><p> <b>Second Quarter 2026 Financial Results</b> </p><ul class="bwlistdisc"> <li> Total revenue of $29.1 million, compared with $24.2 million in the second quarter of 2025 <ul class="bwlistcircle"> <li> HEPZATO KIT™ revenue of $27.1 million, compared to $22.5 million in the second quarter of 2025 </li> <li> CHEMOSAT® revenue of $2.0 million, compared to $1.7 http://www.streetinsider.com/Business+Wire/Delcath+Systems+Reports+Second+Quarter+2026+Results+and+Business+Highlights/26879259.html Thu, 06 Aug 2026 08:01:00 -0400 A.09642568 DCTH O.02931219 O.20371933 http://www.streetinsider.com/Press+Releases/Delcath+Systems+Reports+Second+Quarter+2026+Results+and+Business+Highlights/26879259.html <p class="bwalignc"> <i>Increases 2026 Revenue Guidance to a Range of $104M to $108M <br></br></i><i>Conference Call Today at 8:30 a.m. Eastern Time</i> </p> <p> QUEENSBURY, N.Y.--(BUSINESS WIRE)-- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial results and business highlights for the second quarter ended June 30, 2026. </p><p> <b>Second Quarter 2026 Financial Results</b> </p><ul class="bwlistdisc"> <li> Total revenue of $29.1 million, compared with $24.2 million in the second quarter of 2025 <ul class="bwlistcircle"> <li> HEPZATO KIT™ revenue of $27.1 million, compared to $22.5 million in the second quarter of 2025 </li> <li> CHEMOSAT® revenue of $2.0 million, compared to $1.7 http://www.streetinsider.com/Press+Releases/Delcath+Systems+Reports+Second+Quarter+2026+Results+and+Business+Highlights/26879259.html Thu, 06 Aug 2026 08:01:00 -0400 A.09642568 DCTH O.02931219 O.20371933 http://www.streetinsider.com/Business+Wire/Delcath+Systems+Reports+Second+Quarter+2026+Results+and+Business+Highlights/26879259.html <p class="bwalignc"> <i>Increases 2026 Revenue Guidance to a Range of $104M to $108M <br></br></i><i>Conference Call Today at 8:30 a.m. Eastern Time</i> </p> <p> QUEENSBURY, N.Y.--(BUSINESS WIRE)-- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial results and business highlights for the second quarter ended June 30, 2026. </p><p> <b>Second Quarter 2026 Financial Results</b> </p><ul class="bwlistdisc"> <li> Total revenue of $29.1 million, compared with $24.2 million in the second quarter of 2025 <ul class="bwlistcircle"> <li> HEPZATO KIT™ revenue of $27.1 million, compared to $22.5 million in the second quarter of 2025 </li> <li> CHEMOSAT® revenue of $2.0 million, compared to $1.7 http://www.streetinsider.com/Business+Wire/Delcath+Systems+Reports+Second+Quarter+2026+Results+and+Business+Highlights/26879259.html Thu, 06 Aug 2026 08:01:00 -0400 A.09642568 DCTH O.02931219 O.20371933 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++DELCATH+SYSTEMS%2C+INC.++++++++++++++++++Filed+by%3A+BlackRock%2C+Inc./26827894.html si-local-file:///var/storage/secattach/20260728/26827894.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++DELCATH+SYSTEMS%2C+INC.++++++++++++++++++Filed+by%3A+BlackRock%2C+Inc./26827894.html Tue, 28 Jul 2026 16:45:00 -0400 DCTH O.02931219 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++DELCATH+SYSTEMS%2C+INC.++++++++++++++++++Filed+by%3A+BlackRock%2C+Inc./26827894.html si-local-file:///var/storage/secattach/20260728/26827894.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++DELCATH+SYSTEMS%2C+INC.++++++++++++++++++Filed+by%3A+BlackRock%2C+Inc./26827894.html Tue, 28 Jul 2026 16:45:00 -0400 DCTH O.02931219 http://www.streetinsider.com/Press+Releases/Delcath+Systems+to+Participate+at+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26826829.html <p> QUEENSBURY, N.Y.--(BUSINESS WIRE)-- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the Canaccord Genuity 46th Annual Growth Conference on Tuesday, August 11, 2026, in Boston, MA. </p><p> <b>About Delcath Systems, Inc., HEPZATO KIT and CHEMOSAT <br /></b>Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company's proprietary products, HEPZATO KIT™ (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT® Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), are designed to http://www.streetinsider.com/Press+Releases/Delcath+Systems+to+Participate+at+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26826829.html Tue, 28 Jul 2026 16:01:00 -0400 DCTH O.02931219 http://www.streetinsider.com/Business+Wire/Delcath+Systems+to+Participate+at+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26826829.html <p> QUEENSBURY, N.Y.--(BUSINESS WIRE)-- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the Canaccord Genuity 46th Annual Growth Conference on Tuesday, August 11, 2026, in Boston, MA. </p><p> <b>About Delcath Systems, Inc., HEPZATO KIT and CHEMOSAT <br /></b>Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company's proprietary products, HEPZATO KIT™ (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT® Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), are designed to http://www.streetinsider.com/Business+Wire/Delcath+Systems+to+Participate+at+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26826829.html Tue, 28 Jul 2026 16:01:00 -0400 DCTH O.02931219 http://www.streetinsider.com/Press+Releases/Delcath+Systems+to+Participate+at+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26826829.html <p> QUEENSBURY, N.Y.--(BUSINESS WIRE)-- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the Canaccord Genuity 46th Annual Growth Conference on Tuesday, August 11, 2026, in Boston, MA. </p><p> <b>About Delcath Systems, Inc., HEPZATO KIT and CHEMOSAT <br /></b>Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company's proprietary products, HEPZATO KIT™ (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT® Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), are designed to http://www.streetinsider.com/Press+Releases/Delcath+Systems+to+Participate+at+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26826829.html Tue, 28 Jul 2026 16:01:00 -0400 DCTH O.02931219